Pfizer India and Cipla Limited has announced a partnership where Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India. Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.

Meenakshi Nevatia, country president, Pfizer India, said: “At Pfizer, expanding the reach of our medicines for patients is paramount and we are partnering with Cipla to achieve this common mission.’’ Added Achin Gupta, global chief operating officer, Cipla Ltd.:  “This association with Pfizer aligns with our focus on building a formidable presence across key therapy areas and enhancing access to high quality treatments guided by our purpose of ‘Caring for Life’. Our distribution capabilities will support wider reach for such trusted therapies to patients who need them the most.”

Dalacin C is a part of Pfizer Products India Pvt. Ltd; Corex Dx; Corex LS, Dolonex and Neksium are a part of Pfizer Ltd.